#BEGIN_DRUGCARD DB01839

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
57-55-6

# ChEBI_ID:
16997

# Chemical_Formula:
C3H8O2

# Chemical_IUPAC_Name:
propane-1,2-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
382302

# Description:
A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Solvents
Vehicles

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.92

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+006 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
1,2-Propanediol

# HET_ID:
PGO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C3H8O2/c1-3(5)2-4/h3-5H,2H2,1H3

# InChI_Key:
InChIKey=DNIAPMSPPWPWGF-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00583

# KEGG_Drug_ID:
D00078

# LIMS_Drug_ID:
1839

# Mechanism_Of_Action:
Not Available

# Melting_Point:
-60 °C

# Molecular_Weight_Avg:
76.0944

# Molecular_Weight_Mono:
76.0524295

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1EX0

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.1

# Predicted_LogS:
1.1

# Predicted_Water_Solubility:
9.52e+02 g/l

# Primary_Accession_No:
DB01839

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02572

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(O)CO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:32 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/1,2-Propanediol

# pKa_Isoelectric_Point:
14.9

# Drug_Target_1_Cellular_Location:
Cytoplasm. Secreted protein. Secreted into the blood plasma. Cytoplasmic in most tissues, but also s

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
F13A1

# Drug_Target_1_GenBank_ID_Gene:
M22001

# Drug_Target_1_GenBank_ID_Protein:
182309

# Drug_Target_1_GeneCard_ID:
F13A1

# Drug_Target_1_Gene_Name:
F13A1

# Drug_Target_1_Gene_Sequence:
>2199 bp
ATGTCAGAAACTTCCAGGACCGCCTTTGGAGGCAGAAGAGCAGTTCCACCCAATAACTCT
AATGCAGCGGAAGATGACCTGCCCACAGTGGAGCTTCAGGGCGTGGTGCCCCGGGGCGTC
AACCTGCAAGAGTTTCTTAATGTCACGAGCGTTCACCTGTTCAAGGAGAGATGGGACACT
AACAAGGTGGACCACCACACTGACAAGTATGAAAACAACAAGCTGATTGTCCGCAGAGGG
CAGTCTTTCTATGTGCAGATTGACTTCAGTCGTCCATATGACCCCAGAAGGGATCTCTTC
AGGGTGGAATACGTCATTGGTCGCTACCCACAGGAGAACAAGGGAACCTACATCCCAGTG
CCTATAGTCTCAGAGTTACAAAGTGGAAAGTGGGGGGCCAAGATTGTCATGAGAGAGGAC
AGGTCTGTGCGGCTGTCCATCCAGTCTTCCCCCAAATGTATTGTGGGGAAATTCCGCATG
TATGTTGCTGTCTGGACTCCCTATGGCGTACTTCGAACCAGTCGAAACCCAGAAACAGAC
ACGTACATTCTCTTCAATCCTTGGTGTGAAGATGATGCTGTGTATCTGGACAATGAGAAA
GAAAGAGAAGAGTATGTCCTGAATGACATCGGGGTAATTTTTTATGGAGAGGTCAATGAC
ATCAAGACCAGAAGCTGGAGCTATGGTCAGTTTGAAGATGGCATCCTGGACACTTGCCTG
TATGTGATGGACAGAGCACAAATGGACCTCTCTGGAAGAGGGAATCCCATCAAAGTCAGC
CGTGTGGGGTCTGCAATGGTGAATGCCAAAGATGACGAAGGTGTCCTCGTTGGATCCTGG
GACAATATCTATGCCTATGGCGTCCCCCCATCGGCCTGGACTGGAAGCGTTGACATTCTA
TTGGAATACCGGAGCTCTGAGAATCCAGTCCGGTATGGCCAATGCTGGGTTTTTGCTGGT
GTCTTTAACACATTTTTACGATGCCTTGGAATACCAGCAAGAATTGTTACCAATTATTTC
TCTGCCCATGATAATGATGCCAATTTGCAAATGGACATCTTCCTGGAAGAAGATGGGAAC
GTGAATTCCAAACTCACCAAGGATTCAGTGTGGAACTACCACTGCTGGAATGAAGCATGG
ATGACAAGGCCTGACCTTCCTGTTGGATTTGGAGGCTGGCAAGCTGTGGACAGCACCCCC
CAGGAAAATAGCGATGGCATGTATCGGTGTGGCCCCGCCTCGGTTCAAGCCATCAAGCAC
GGCCATGTCTGCTTCCAATTTGATGCACCTTTTGTTTTTGCAGAGGTCAACAGCGACCTC
ATTTACATTACAGCTAAGAAAGATGGCACTCATGTGGTGGAAAATGTGGATGCCACCCAC
ATTGGGAAATTAATTGTGACCAAACAAATTGGAGGAGATGGCATGATGGATATTACTGAT
ACTTACAAATTCCAAGAAGGTCAAGAAGAAGAGAGATTGGCCCTAGAAACTGCCCTGATG
TACGGAGCTAAAAAGCCCCTCAACACAGAAGGTGTCATGAAATCAAGGTCCAACGTTGAC
ATGGACTTTGAAGTGGAAAATGCTGTGCTGGGAAAAGACTTCAAGCTCTCCATCACCTTC
CGGAACAACAGCCACAACCGTTACACCATCACAGCTTATCTCTCAGCCAACATCACCTTC
TACACCGGGGTCCTGAAGGCAGAATTCAAGAAGGAGACGTTCGACGTGACGCTGGAGCCC
TTGTCCTTCAAGAAAGAGGCGGTGCTGATCCAAGCCGGCGAGTACATGGGTCAGCTGCTG
GAACAAGCGTCCCTGCACTTCTTTGTCACAGCTCGCATCAATGAGACCAGGGATGTTCTG
GCCAAGCAAAAGTCCACCGTGCTAACCATCCCTGAGATCATCATCAAGGTCCGTGGCACT
CAGGTAGTTGGTTCTGACATGACTGTGACAGTTCAGTTTACCAATCCTTTAAAAGAAACC
CTGCGAAATGTCTGGGTACACCTGGATGGTCCTGGAGTAACAAGACCAATGAAGAAGATG
TTCCGTGAAATCCGGCCCAACTCCACCGTGCAGTGGGAAGAAGTGTGCCGGCCCTGGGTC
TCTGGGCATCGGAAGCTGATAGCCAGCATGAGCAGTGACTCCCTGAGACATGTGTATGGC
GAGCTGGACGTGCAGATTCAAAGACGACCTTCCATGTGA

# Drug_Target_1_General_Function:
Involved in protein-glutamine gamma-glutamyltransferase activity

# Drug_Target_1_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
1353995	Board P, Coggan M, Miloszewski K: Identification of a point mutation in factor XIII A subunit deficiency. Blood. 1992 Aug 15;80(4):937-41.
2877456	Takahashi N, Takahashi Y, Putnam FW: Primary structure of blood coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8019-23.
2877457	Grundmann U, Amann E, Zettlmeissl G, Kupper HA: Characterization of cDNA coding for human factor XIIIa. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8024-8.
2901091	Ichinose A, Davie EW: Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5829-33.
3026437	Ichinose A, Hendrickson LE, Fujikawa K, Davie EW: Amino acid sequence of the a subunit of human factor XIII. Biochemistry. 1986 Nov 4;25(22):6900-6.
4811064	Takagi T, Doolittle RF: Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry. 1974 Feb 12;13(4):750-6.
7660355	Yee VC, Pedersen LC, Bishop PD, Stenkamp RE, Teller DC: Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII. Thromb Res. 1995 Jun 1;78(5):389-97.
7913750	Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp RE, Teller DC: Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7296-300.
7913909	Suzuki K, Iwata M, Ito S, Matsui K, Uchida A, Mizoi Y: Molecular basis for subtypic differences of the "a" subunit of coagulation factor XIII with description of the genesis of the subtypes. Hum Genet. 1994 Aug;94(2):129-35.
9515726	Weiss MS, Metzner HJ, Hilgenfeld R: Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett. 1998 Feb 27;423(3):291-6.
9763561	Kangsadalampai S, Board PG: The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood. 1998 Oct 15;92(8):2766-70.
9988734	Fox BA, Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp RE, Teller DC: Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by x-ray crystallography. J Biol Chem. 1999 Feb 19;274(8):4917-23.

# Drug_Target_1_HGNC_ID:
HGNC:3531

# Drug_Target_1_HPRD_ID:
00604

# Drug_Target_1_ID:
6

# Drug_Target_1_Locus:
6p25.3-p24.3

# Drug_Target_1_Molecular_Weight:
83137

# Drug_Target_1_Name:
Coagulation factor XIII A chain

# Drug_Target_1_Number_of_Residues:
731

# Drug_Target_1_PDB_ID:
1FIE

# Drug_Target_1_Pathway:
Acenocoumarol Pathway	SMP00269
Alteplase Pathway	SMP00280
Aminocaproic Acid Pathway	SMP00286
Anistreplase Pathway	SMP00281
Aprotinin Pathway	SMP00288
Ardeparin Pathway	SMP00275
Argatroban Pathway	SMP00276
Bivalirudin Pathway	SMP00277
Dicumarol Pathway	SMP00270
Enoxaparin Pathway	SMP00272
Fondaparinux Pathway	SMP00273
Heparin Pathway	SMP00274
Lepirudin Pathway	SMP00278
Phenprocoumon Pathway	SMP00271
Reteplase Pathway	SMP00285
Streptokinase Pathway	SMP00282
Tenecteplase Pathway	SMP00283
Tranexamic Acid Pathway	SMP00287
Urokinase Pathway	SMP00284
Warfarin Pathway	SMP00268
Ximelagatran Pathway	SMP00279

# Drug_Target_1_Pfam_Domain_Function:
PF00868	Transglut_N
PF01841	Transglut_core

# Drug_Target_1_Protein_Sequence:
>Coagulation factor XIII A chain precursor
SETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPRGVNLQEFLNVTSVHLFKERWDTN
KVDHHTDKYENNKLIVRRGQSFYVQIDFSRPYDPRRDLFRVEYVIGRYPQENKGTYIPVP
IVSELQSGKWGAKIVMREDRSVRLSIQSSPKCIVGKFRMYVAVWTPYGVLRTSRNPETDT
YILFNPWCEDDAVYLDNEKEREEYVLNDIGVIFYGEVNDIKTRSWSYGQFEDGILDTCLY
VMDRAQMDLSGRGNPIKVSRVGSAMVNAKDDEGVLVGSWDNIYAYGVPPSAWTGSVDILL
EYRSSENPVRYGQCWVFAGVFNTFLRCLGIPARIVTNYFSAHDNDANLQMDIFLEEDGNV
NSKLTKDSVWNYHCWNEAWMTRPDLPVGFGGWQAVDSTPQENSDGMYRCGPASVQAIKHG
HVCFQFDAPFVFAEVNSDLIYITAKKDGTHVVENVDATHIGKLIVTKQIGGDGMMDITDT
YKFQEGQEEERLALETALMYGAKKPLNTEGVMKSRSNVDMDFEVENAVLGKDFKLSITFR
NNSHNRYTITAYLSANITFYTGVPKAEFKKETFDVTLEPLSFKKEAVLIQAGEYMGQLLE
QASLHFFVTARINETRDVLAKQKSTVLTIPEIIIKVRGTQVVGSDMTVTVQFTNPLKETL
RNVWVHLDGPGVTRPMKKMFREIRPNSTVQWEEVCRPWVSGHRKLIASMSSDSLRHVYGE
LDVQIQRRPSM

# Drug_Target_1_Reaction:
protein glutamine + alkylamine = protein N5-alkylglutamine + NH3

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl- epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin

# Drug_Target_1_SwissProt_ID:
P00488

# Drug_Target_1_SwissProt_Name:
F13A_HUMAN

# Drug_Target_1_Synonyms:
Coagulation factor XIII A chain precursor
Coagulation factor XIIIa
EC 2.3.2.13
Protein-glutamine gamma-glutamyltransferase A chain
Transglutaminase A chain

# Drug_Target_1_Theoretical_pI:
5.95

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Periplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
D14594

# Drug_Target_2_GenBank_ID_Protein:
4521186

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
linB

# Drug_Target_2_Gene_Sequence:
>891 bp
ATGAGCCTCGGCGCAAAGCCATTTGGCGAGAAGAAATTCATTGAGATCAAGGGCCGGCGC
ATGGCCTATATCGATGAAGGGACCGGCGATCCGATCCTCTTCCAGCACGGCAATCCGACG
TCGTCCTATCTGTGGCGCAATATCATGCCGCATTGCGCCGGGCTGGGACGGCTGATCGCC
TGTGACCTGATCGGCATGGGCGATTCGGACAAGCTCGATCCGTCGGGGCCCGAGCGTTAT
GCCTATGCCGAGCATCGTGACTATCTCGACGCGCTGTGGGAGGCGCTCGATCTCGGGGAC
AGGGTTGTTCTGGTCGTGCATGACTGGGGGTCCGCCCTCGGCTTCGACTGGGCCCGCCGC
CACCGCGAGCGTGTACAGGGGATTGCCTATATGGAAGCGATCGCCATGCCGATCGAATGG
GCGGATTTTCCCGAACAGGATCGCGATCTGTTTCAGGCCTTTCGCTCGCAGGCGGGCGAA
GAATTGGTGTTGCAGGACAATGTTTTTGTCGAACAAGTTCTCCCCGGATTGATCCTGCGC
CCCTTAAGCGAAGCGGAGATGGCCGCCTATCGCGAGCCCTTCCTCGCCGCCGGCGAAGCC
CGTCGACCGACCCTGTCTTGGCCTCGCCAAATCCCGATCGCAGGCACCCCGGCCGACGTG
GTCGCGATCGCCCGGGACTATGCCGGCTGGCTCAGCGAAAGCCCGATTCCGAAACTCTTC
ATCAACGCCGAGCCGGGAGCCCTGACCACGGGCCGAATGCGCGACTTCTGCCGCACATGG
CCAAACCAGACCGAAATCACGGTCGCAGGCGCCCATTTCATCCAGGAGGACAGTCCGGAC
GAGATTGGCGCGGCGATTGCGGCGTTTGTCCGGCGATTGCGCCCAGCATAA

# Drug_Target_2_General_Function:
Involved in haloalkane dehalogenase activity

# Drug_Target_2_General_References:
10100638	Hynkova K, Nagata Y, Takagi M, Damborsky J: Identification of the catalytic triad in the haloalkane dehalogenase from Sphingomonas paucimobilis UT26. FEBS Lett. 1999 Mar 5;446(1):177-81.
10329794	Smatanova I, Nagata Y, Svensson LA, Takagi M, Marek J: Crystallization and preliminary X-ray diffraction analysis of haloalkane dehalogenase LinB from Sphingomonas paucimobilis UT26. Acta Crystallogr D Biol Crystallogr. 1999 Jun;55(Pt 6):1231-3.
10464214	Nagata Y, Futamura A, Miyauchi K, Takagi M: Two different types of dehalogenases, LinA and LinB, involved in gamma-hexachlorocyclohexane degradation in Sphingomonas paucimobilis UT26 are localized in the periplasmic space without molecular processing. J Bacteriol. 1999 Sep;181(17):5409-13.
11087355	Marek J, Vevodova J, Smatanova IK, Nagata Y, Svensson LA, Newman J, Takagi M, Damborsky J: Crystal structure of the haloalkane dehalogenase from Sphingomonas paucimobilis UT26. Biochemistry. 2000 Nov 21;39(46):14082-6.
11939779	Oakley AJ, Prokop Z, Bohac M, Kmunicek J, Jedlicka T, Monincova M, Kuta-Smatanova I, Nagata Y, Damborsky J, Wilce MC: Exploring the structure and activity of haloalkane dehalogenase from Sphingomonas paucimobilis UT26: evidence for product- and water-mediated inhibition. Biochemistry. 2002 Apr 16;41(15):4847-55.
12450392	Bohac M, Nagata Y, Prokop Z, Prokop M, Monincova M, Tsuda M, Koca J, Damborsky J: Halide-stabilizing residues of haloalkane dehalogenases studied by quantum mechanic calculations and site-directed mutagenesis. Biochemistry. 2002 Dec 3;41(48):14272-80.
12450824	Kumari R, Subudhi S, Suar M, Dhingra G, Raina V, Dogra C, Lal S, van der Meer JR, Holliger C, Lal R: Cloning and characterization of lin genes responsible for the degradation of Hexachlorocyclohexane isomers by Sphingomonas paucimobilis strain B90. Appl Environ Microbiol. 2002 Dec;68(12):6021-8.
7691794	Nagata Y, Nariya T, Ohtomo R, Fukuda M, Yano K, Takagi M: Cloning and sequencing of a dehalogenase gene encoding an enzyme with hydrolase activity involved in the degradation of gamma-hexachlorocyclohexane in Pseudomonas paucimobilis. J Bacteriol. 1993 Oct;175(20):6403-10.
9293022	Nagata Y, Miyauchi K, Damborsky J, Manova K, Ansorgova A, Takagi M: Purification and characterization of a haloalkane dehalogenase of a new substrate class from a gamma-hexachlorocyclohexane-degrading bacterium, Sphingomonas paucimobilis UT26. Appl Environ Microbiol. 1997 Sep;63(9):3707-10.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2281

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
33108

# Drug_Target_2_Name:
Haloalkane dehalogenase

# Drug_Target_2_Number_of_Residues:
296

# Drug_Target_2_PDB_ID:
1MJ5

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00561	Abhydrolase_1

# Drug_Target_2_Protein_Sequence:
>Haloalkane dehalogenase
MSLGAKPFGEKKFIEIKGRRMAYIDEGTGDPILFQHGNPTSSYLWRNIMPHCAGLGRLIA
CDLIGMGDSDKLDPSGPERYAYAEHRDYLDALWEALDLGDRVVLVVHDWGSALGFDWARR
HRERVQGIAYMEAIAMPIEWADFPEQDRDLFQAFRSQAGEELVLQDNVFVEQVLPGLILR
PLSEAEMAAYREPFLAAGEARRPTLSWPRQIPIAGTPADVVAIARDYAGWLSESPIPKLF
INAEPGALTTGRMRDFCRTWPNQTEITVAGAHFIQEDSPDEIGAAIAAFVRRLRPA

# Drug_Target_2_Reaction:
1-haloalkane + H2O = a primary alcohol + halide

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes hydrolytic cleavage of carbon-halogen bonds in halogenated aliphatic compounds, leading to the formation of the corresponding primary alcohols, halide ions and protons. Has a broad substrate specificity since not only monochloroalkanes (C3 to C10) but also dichloroalkanes (> C3), bromoalkanes, and chlorinated aliphatic alcohols were good substrates. Shows almost no activity with 1,2-dichloroethane, but very high activity with the brominated analog. Is involved in the degradation of the important environmental pollutant gamma-hexachlorocyclohexane (lindane) as it also catalyzes conversion of 1,3,4,6-tetrachloro- 1,4-cyclohexadiene (1,4-TCDN) to 2,5-dichloro-2,5-cyclohexadiene- 1,4-diol (2,5-DDOL) via the intermediate 2,4,5-trichloro-2,5- cyclohexadiene-1-ol (2,4,5-DNOL)

# Drug_Target_2_SwissProt_ID:
P51698

# Drug_Target_2_SwissProt_Name:
LINB_PSEPA

# Drug_Target_2_Synonyms:
1,3,4,6-tetrachloro-1,4- cyclohexadiene hydrolase
1,4-TCDN chlorohydrolase
EC 3.8.1.5

# Drug_Target_2_Theoretical_pI:
4.80

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L06213

# Drug_Target_3_GenBank_ID_Protein:
153220

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
cs1

# Drug_Target_3_Gene_Sequence:
>975 bp
ATGACCTCAGTGGACTGCACCGCGTACGGCCCCGAGCTGCGCGCGCTCGCCGCCCGGCTG
CCCCGGACCCCCCGGGCCGACCTGTACGCCTTCCTGGACGCCGCGCACACAGCCGCCGCC
TCGCTCCCCGGCGCCCTCGCCACCGCGCTGGACACCTTCAACGCCGAGGGCAGCGAGGAC
GGCCATCTGCTGCTGCGCGGCCTCCCGGTGGAGGCCGACGCCGACCTCCCCACCACCCCG
AGCAGCACCCCGGCGCCCGAGGACCGCTCCCTGCTGACCATGGAGGCCATGCTCGGACTG
GTGGGCCGCCGGCTCGGTCTGCACACGGGGTACCGGGAGCTGCGCTCGGGCACGGTCTAC
CACGACGTGTACCCGTCGCCCGGCGCGCACCACCTGTCCTCGGAGACCTCCGAGACGCTG
CTGGAGTTCCACACGGAGATGGCCTACCACCGGCTCCAGCCGAACTACGTCATGCTGGCC
TGCTCCCGGGCCGACCACGAGCGCACGGCGGCCACACTCGTCGCCTCGGTCCGCAAGGCG
CTGCCCCTGCTGGACGAGAGGACCCGGGCCCGGCTCCTCGACCGGAGGATGCCCTGCTGC
GTGGATGTGGCCTTCCGCGGCGGGGTGGACGACCCGGGCGCCATCGCCCAGGTCAAACCG
CTCTACGGGGACGCGGACGATCCCTTCCTCGGGTACGACCGCGAGCTGCTGGCGCCGGAG
GACCCCGCGGACAAGGAGGCCGTCGCCGCCCTGTCCAAGGCGCTCGACGAGGTCACGGAG
GCGGTGTATCTGGAGCCCGGCGATCTGCTGATCGTCGACAACTTCCGCACCACGCACGCG
CGGACGCCGTTCTCGCCCCGCTGGGACGGGAAGGACCGCTGGCTGCACCGCGTCTACATC
CGCACCGACCGCAATGGACAGCTCTCCGGCGGCGAGCGCGCGGGCGACGTCGTCGCCTTC
ACACCGCGCGGCTGA

# Drug_Target_3_General_Function:
Involved in oxidoreductase activity

# Drug_Target_3_General_References:
1472501	Marsh EN, Chang MD, Townsend CA: Two isozymes of clavaminate synthase central to clavulanic acid formation: cloning and sequencing of both genes from Streptomyces clavuligerus. Biochemistry. 1992 Dec 22;31(50):12648-57.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2400

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
35370

# Drug_Target_3_Name:
Clavaminate synthase 1

# Drug_Target_3_Number_of_Residues:
324

# Drug_Target_3_PDB_ID:
1GVG

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02668	TauD

# Drug_Target_3_Protein_Sequence:
>Clavaminate synthase 1
MTSVDCTAYGPELRALAARLPRTPRADLYAFLDAAHTAAASLPGALATALDTFNAEGSED
GHLLLRGLPVEADADLPTTPSSTPAPEDRSLLTMEAMLGLVGRRLGLHTGYRELRSGTVY
HDVYPSPGAHHLSSETSETLLEFHTEMAYHRLQPNYVMLACSRADHERTAATLVASVRKA
LPLLDERTRARLLDRRMPCCVDVAFRGGVDDPGAIAQVKPLYGDADDPFLGYDRELLAPE
DPADKEAVAALSKALDEVTEAVYLEPGDLLIVDNFRTTHARTPFSPRWDGKDRWLHRVYI
RTDRNGQLSGGERAGDVVAFTPRG

# Drug_Target_3_Reaction:
(1) deoxyamidinoproclavaminate + 2-oxoglutarate + O2 = amidinoproclavaminate + succinate + CO2

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Deoxyamidinoproclavaminate + 2-oxoglutarate + O(2) = amidinoproclavaminate + succinate + CO(2) + H(2)O

# Drug_Target_3_SwissProt_ID:
Q05581

# Drug_Target_3_SwissProt_Name:
CAS1_STRCL

# Drug_Target_3_Synonyms:
CAS1
CS1
Clavaminic acid synthetase 1
EC 1.14.11.21

# Drug_Target_3_Theoretical_pI:
5.24

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
M31059

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
fucO

# Drug_Target_4_Gene_Sequence:
Not Available

# Drug_Target_4_General_Function:
Energy production and conversion

# Drug_Target_4_General_References:
2553671	Chen YM, Lu Z, Lin EC: Constitutive activation of the fucAO operon and silencing of the divergently transcribed fucPIK operon by an IS5 element in Escherichia coli mutants selected for growth on L-1,2-propanediol. J Bacteriol. 1989 Nov;171(11):6097-105.
2661535	Conway T, Ingram LO: Similarity of Escherichia coli propanediol oxidoreductase (fucO product) and an unusual alcohol dehydrogenase from Zymomonas mobilis and Saccharomyces cerevisiae. J Bacteriol. 1989 Jul;171(7):3754-9.
2664711	Lu Z, Lin EC: The nucleotide sequence of Escherichia coli genes for L-fucose dissimilation. Nucleic Acids Res. 1989 Jun 26;17(12):4883-4.
8385012	Shao Z, Newman EB: Sequencing and characterization of the sdaB gene from Escherichia coli K-12. Eur J Biochem. 1993 Mar 15;212(3):777-84.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3725

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
40645

# Drug_Target_4_Name:
Lactaldehyde reductase

# Drug_Target_4_Number_of_Residues:
383

# Drug_Target_4_PDB_ID:
1RRM

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00465	Fe-ADH

# Drug_Target_4_Protein_Sequence:
>Lactaldehyde reductase
MMANRMILNETAWFGRGAVGALTDEVKRRGYQKALIVTDKTLVQCGVVAKVTDKMDAAGL
AWAIYDGVVPNPTITVVKEGLGVFQNSGADYLIAIGGGSPQDTCKAIGIISNNPEFADVR
SLEGLSPTNKPSVPILAIPTTAGTAAEVTINYVITDEEKRRKFVCVDPHDIPQVAFIDAD
MMDGMPPALKAATGVDALTHAIEGYITRGAWALTDALHIKAIEIIAGALRGSVAGDKDAG
EEMALGQYVAGMGFSNVGLGLVHGMAHPLGAFYNTPHGVANAILLPHVMRYNADFTGEKY
RDIARVMGVKVEGMSLEEARNAAVEAVFALNRDVGIPPHLRDVGVRKEDIPALAQAALDD
VCTGGNPREATLEDIVELYHTAW

# Drug_Target_4_Reaction:
(R)[or (S)]-propane-1,2-diol + NAD+ = (R)[or (S)]-lactaldehyde + NADH + H+

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
(R)[or (S)]-propane-1,2-diol + NAD(+) = (R)[or (S)]-lactaldehyde + NADH

# Drug_Target_4_SwissProt_ID:
P0A9S1

# Drug_Target_4_SwissProt_Name:
FUCO_ECOLI

# Drug_Target_4_Synonyms:
EC 1.1.1.77
Propanediol oxidoreductase

# Drug_Target_4_Theoretical_pI:
4.91

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
AY112989

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
dhaB1

# Drug_Target_5_Gene_Sequence:
>2364 bp
ATGATAAGTAAAGGATTTAGTACCCAAACAGAAAGAATAAATATTTTAAAGGCTCAAATA
TTAAATGCTAAACCATGTGTTGAATCAGAAAGAGCAATATTAATAACAGAATCATTTAAA
CAAACAGAAGGCCAGCCAGCAATTTTAAGAAGAGCATTGGCATTGAAACACATACTTGAA
AATATCCCTATAACAATTAGAGATCAAGAACTTATAGTGGGAAGTTTAACTAAAGAACCA
AGGTCTTCACAAGTATTTCCTGAGTTTTCTAATAAGTGGTTACAAGATGAATTGGATAGA
TTAAATAAGAGAACTGGAGATGCATTCCAAATTTCAGAAGAAAGTAAAGAAAAATTAAAA
GATGTCTTTGAGTATTGGAATGGAAAGACAACAAGTGAGTTAGCAACTTCATATATGACA
GAGGAAACAAGAGAGGCAGTAAATTGTGATGTATTTACTGTAGGAAACTACTATTATAAT
GGCGTAGGACATGTATCTGTAGATTATGGAAAAGTATTAAGGGTTGGATTTAATGGGATT
ATAAATGAGGCTAAGGAACAATTAGAAAAAAACAGGAGTATAGATCCTGATTTTATAAAG
AAAGAAAAATTCCTAAATAGTGTTATTATCTCATGCGAAGCTGCAATAACATATGTAAAT
AGATATGCTAAAAAGGCTAAAGAGATTGCAGATAATACAAGTGATGCAAAAAGAAAAGCT
GAATTAAATGAAATAGCAAAAATTTGTTCAAAAGTTTCAGGAGAGGGAGCTAAATCTTTC
TATGAAGCATGTCAATTATTTTGGTTTATTCATGCAATAATAAATATAGAATCTAATGGA
CATTCTATTTCTCCAGCTAGATTTGATCAATACATGTATCCATATTATGAAAATGATAAA
AATATAACAGATAAGTTTGCTCAAGAATTAATAGATTGTATCTGGATTAAATTAAATGAT
ATTAATAAAGTAAGAGATGAGATTTCAACTAAACATTTTGGTGGTTACCCAATGTATCAA
AACTTAATTGTTGGGGGTCAAAATTCAGAAGGAAAAGATGCAACTAATAAAGTATCATAT
ATGGCATTAGAAGCAGCTGTCCATGTAAAGTTGCCTCAGCCATCTTTGTCAGTAAGAATA
TGGAATAAGACTCCAGATGAATTTTTGCTTAGAGCAGCAGAATTAACTAGAGAAGGGTTA
GGACTTCCTGCTTATTATAATGATGAAGTTATTATTCCAGCATTAGTTTCTAGAGGTCTT
ACATTAGAAGATGCAAGAGACTACGGAATAATTGGATGTGTTGAACCACAAAAGCCAGGA
AAAACAGAAGGATGGCATGATTCAGCATTCTTTAATCTTGCAAGAATAGTAGAGTTAACT
ATAAATTCTGGATTTGATAAAAATAAACAGATTGGACCTAAAACTCAAAATTTTGAAGAA
ATGAAATCCTTTGATGAATTCATGAAAGCTTATAAAGCTCAAATGGAGTATTTTGTAAAA
CATATGTGCTGTGCTGATAATTGCATAGATATTGCACATGCAGAAAGAGCTCCATTACCT
TTCTTGTCATCAATGGTTGATAATTGTATCGGAAAAGGAAAGAGCCTTCAAGATGGTGGT
GCAGAATATAACTTCAGTGGACCACAAGGTGTTGGAGTAGCTAATATTGGAGATTCATTA
GTTGCAGTTAAAAAAATTGTGTTTGATGAAAATAAGATTACTCCTTCAGAATTAAAGAAA
ACATTAAATAATGATTTTAAAAATTCAGAAGAAATACAAGCCTTACTAAAAAATGCTCCT
AAGTTTGGAAATGATATTGATGAAGTTGATAATTTAGCTAGAGAGGGTGCATTAGTATAC
TGTAGAGAAGTTAATAAATATACAAATCCAAGGGGAGGAAATTTTCAACCAGGATTATAT
CCATCTTCAATTAATGTATATTTTGGAAGCTTAACAGGTGCTACTCCAGATGGAAGGAAA
TCCGGACAACCATTAGCTGATGGGGTTTCTCCATCAAGAGGCTGTGATGTATCTGGACCT
ACTGCAGCTTGTAACTCAGTTAGTAAATTAGATCATTTTATAGCTTCAAATGGAACTTTA
TTTAATCAAAAATTCCATCCGTCAGCATTAAAAGGTGATAATGGATTAATGAATTTATCA
TCATTAATAAGAAGTTATTTTGATCAAAAGGGATTTCATGTTCAATTTAATGTAATAGAT
AAAAAAATATTACTTGCAGCACAAAAAAATCCTGAAAAATATCAAGATTTAATTGTTAGA
GTTGCAGGATATAGTGCACAGTTCATTTCTTTAGATAAATCTATTCAAAATGATATTATT
GCAAGAACTGAACATGTTATGTAA

# Drug_Target_5_General_Function:
Involved in catalytic activity

# Drug_Target_5_General_References:
12704244	Raynaud C, Sarcabal P, Meynial-Salles I, Croux C, Soucaille P: Molecular characterization of the 1,3-propanediol (1,3-PD) operon of Clostridium butyricum. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5010-5. Epub 2003 Apr 18.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
4387

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
88048

# Drug_Target_5_Name:
Glycerol dehydratase

# Drug_Target_5_Number_of_Residues:
787

# Drug_Target_5_PDB_ID:
1R9E

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF01228	Gly_radical
PF02901	PFL

# Drug_Target_5_Protein_Sequence:
>Glycerol dehydratase
MISKGFSTQTERINILKAQILNAKPCVESERAILITESFKQTEGQPAILRRALALKHILE
NIPITIRDQELIVGSLTKEPRSSQVFPEFSNKWLQDELDRLNKRTGDAFQISEESKEKLK
DVFEYWNGKTTSELATSYMTEETREAVNCDVFTVGNYYYNGVGHVSVDYGKVLRVGFNGI
INEAKEQLEKNRSIDPDFIKKEKFLNSVIISCEAAITYVNRYAKKAKEIADNTSDAKRKA
ELNEIAKICSKVSGEGAKSFYEACQLFWFIHAIINIESNGHSISPARFDQYMYPYYENDK
NITDKFAQELIDCIWIKLNDINKVRDEISTKHFGGYPMYQNLIVGGQNSEGKDATNKVSY
MALEAAVHVKLPQPSLSVRIWNKTPDEFLLRAAELTREGLGLPAYYNDEVIIPALVSRGL
TLEDARDYGIIGCVEPQKPGKTEGWHDSAFFNLARIVELTINSGFDKNKQIGPKTQNFEE
MKSFDEFMKAYKAQMEYFVKHMCCADNCIDIAHAERAPLPFLSSMVDNCIGKGKSLQDGG
AEYNFSGPQGVGVANIGDSLVAVKKIVFDENKITPSELKKTLNNDFKNSEEIQALLKNAP
KFGNDIDEVDNLAREGALVYCREVNKYTNPRGGNFQPGLYPSSINVYFGSLTGATPDGRK
SGQPLADGVSPSRGCDVSGPTAACNSVSKLDHFIASNGTLFNQKFHPSALKGDNGLMNLS
SLIRSYFDQKGFHVQFNVIDKKILLAAQKNPEKYQDLIVRVAGYSAQFISLDKSIQNDII
ARTEHVM

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
Q8GEZ8

# Drug_Target_5_SwissProt_Name:
Q8GEZ8_CLOBU

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
6.46

# Drug_Target_5_Transmembrane_Regions:
None

#END_DRUGCARD DB01839
